Drug intelligence / Profile preview

flucloxacillin + gentamicin

Development stage
Unknown
Modality
Small Molecules
Administration
Oral (for Flucloxacillin)[6][8], Intravenous[7], Intramuscular[7]
01

Overview

Flucloxacillin + gentamicin is a combination of two antibiotics used primarily for the treatment and prophylaxis of serious bacterial infections, especially those caused by susceptible gram-positive organisms such as Staphylococcus aureus. Flucloxacillin is a beta-lactam antibiotic (penicillin class) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It is stable against many beta-lactamases. Gentamicin is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and resulting in bactericidal activity. The combination offers synergistic effects—flucloxacillin disrupts cell wall integrity while gentamicin inhibits protein synthesis—resulting in enhanced bactericidal action and inhibition of exotoxin production, which can be particularly important in toxin-mediated diseases like toxic shock syndrome[1][4]. This regimen may be considered as an alternative to clindamycin-based therapy for severe staphylococcal or streptococcal infections.

02

Targets

30S A-site (Bacterial ribosomal 30S A-site)NeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on flucloxacillin + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on flucloxacillin + gentamicin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call